The Latest Breaking News from MRK

Yesterday, with Merck trading at $103.94, the November put option with a strike price of $100 was trading around $1.78. Traders selling this put would receive $178 in option premium.

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.

The pharmaceutical sector is expanding due to advanced technologies such as AI and new drug discoveries. Hence, quality pharma stocks GoodRx Holdings (GDRX), Merck & Co. (MRK), and Sanofi (SNY) might be profitable investments right now. Read on.

The pharmaceutical industry looks well-positioned for long-term growth. Therefore, fundamentally strong Merck & Co (MRK), Pfizer (PFE), and Lipocine (LPCN) could be ideal value investments now. Keep reading.

The pharma industry is well-positioned to witness significant growth due to the continuous advancements in artificial intelligence and increasing demand for innovative drugs. Therefore, fundamentally strong pharma stocks Merck & Co. (MRK), Astellas Pharma (ALPMY), and Taro Pharmaceutical (TARO), which seem to be trading at a discount, might be solid…

MMM and MRK have both underperformed markets in 2023, but offer healthy yields for value-minded investors. Which of these dividend stocks is a better pick for your portfolio right now?

The long-term prospects of Merck (MRK) look bright due to its latest acquisitions and solid drug pipeline. Therefore, investing in this stock could help generate substantial returns in the long run. Keep reading….

The Federal Reserve’s interest rate hikes since last year showed results as annual inflation dropped for the ninth consecutive month in March. However, with the Fed likely to hike the interest rate at the policy meeting next month, the risk of a recession looms. In this scenario, it could be…

As investors continue to digest the news of the recent bank collapses and the Federal Reserve’s quarter-percentage-point rate hike, the stock market outlook seems bumpy for some time. With speculations of an economic slowdown, investing in prominent large-cap stocks Johnson & Johnson (JNJ), Visa (V), and Merck & Co. (MRK)…

The worst banking crisis since 2008 could not stop the Fed from raising the benchmark interest rate. The possibility of further policy tightening and strict lending standards for banks might push the economy into a recession this year. Therefore, investing in large-cap pharma stocks Johnson & Johnson (JNJ), Merck &…

Amid the banking turmoil and the Fed’s latest quarter-point rate hike, the odds of a recession are back on the rise. Hence, it could be wise to invest in no-brainer stocks Taiwan Semiconductor Manufacturing (TSM), Novo Nordisk (NVO), and Merck & Co. (MRK) now. Read more….